Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in TTP pools mediated by 5-bromo-2'-deoxyuridine exposure in a human glioblastoma cell line.

D S Shewach1, J Ellero, W R Mancini

  • 1Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0504.

Biochemical Pharmacology
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.

Oncogene·2016
Same author

Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.

Cell death and differentiation·2015
Same author

Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir.

Cancer gene therapy·2011
Same author

MLH1 deficiency enhances tumor cell sensitivity to ganciclovir.

Cancer gene therapy·2009
Same author

GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity.

Gene therapy·2005
Same author

Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy.

Gene therapy·2002
Same journal

Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology.

Biochemical pharmacology·2026
Same journal

hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation.

Biochemical pharmacology·2026
Same journal

CD55 glycosylation promotes ferroptotic stress tolerance in CD55-high triple-negative breast cancer.

Biochemical pharmacology·2026
Same journal

The role of Piezo1 in skeletal muscle physiology and pathology: from mechanosensing to precision therapy.

Biochemical pharmacology·2026
Same journal

Notch signaling in anti-VEGF resistant arteriolar choroidal neovascularization.

Biochemical pharmacology·2026
Same journal

Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease.

Biochemical pharmacology·2026
See all related articles

5-bromo-2'-deoxyuridine (BUdR) enhances its DNA incorporation by decreasing cellular TTP pools. This mechanism optimizes conditions for BUdR

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • 5-bromo-2 -deoxyuridine (BUdR) exhibits antitumor and radiosensitizing effects.
  • These properties are linked to its incorporation into cellular DNA.
  • Optimizing BUdR incorporation requires understanding its metabolic pathway to DNA precursors.

Purpose of the Study:

  • To investigate the metabolism of BUdR to its DNA precursor, 5-bromo-2 -deoxyuridine-5 -triphosphate (BrdUTP).
  • To determine the conditions that optimize BrdUTP incorporation into DNA in U251 human glioblastoma cells.
  • To elucidate the relationship between BUdR concentration, BrdUTP levels, and cellular nucleotide pools.

Main Methods:

  • Cultured U251 human glioblastoma cells were exposed to varying concentrations of BUdR.

Related Experiment Videos

  • Cellular levels of BrdUTP, dCTP, and TTP were quantified.
  • The rate of BrdUMP incorporation into DNA was measured over time.

    • Main Results:

    • BrdUTP rapidly accumulated in U251 cells, reaching steady-state within 2 hours.
    • BrdUTP accumulation was dose-dependent on exogenous BUdR up to 100 microM.
    • BUdR exposure led to significant decreases in cellular dCTP and TTP pools, which reversed upon BUdR removal.
    • BrdUMP incorporation into DNA was linear with time while BrdUTP levels remained constant.
    • 5-fluoro-2 -deoxyuridine (FUdR) did not enhance BrdUMP incorporation or affect TTP pools.

    Conclusions:

    • The decrease in cellular TTP pools induced by BrdUTP facilitates enhanced incorporation of BUdR into DNA.
    • This self-amplifying mechanism optimizes the conditions for BUdR's therapeutic effects in glioblastoma cells.
    • Understanding this metabolic pathway is crucial for developing targeted cancer therapies.